Department of Integrative Bioscience and Biotechnology, Pohang University of Science and Technology, Pohang, Korea.
J Korean Med Sci. 2010 Dec;25(12):1792-7. doi: 10.3346/jkms.2010.25.12.1792. Epub 2010 Nov 24.
To investigate the efficacy and safety of desmopressin in patients with mixed nocturia, Patients aged ≥ 18 yr with mixed nocturia (≥ 2 voids/night and a nocturnal polyuria index [NPi] >33% and a nocturnal bladder capacity index [NBCi] >1) were recruited. The optimum dose of oral desmopressin was determined during a 3-week dose-titration period and the determined dose was maintained for 4 weeks. The efficacy was assessed by the frequency-volume charts and the sleep questionnaire. The primary endpoint was the proportion of patients with a 50% or greater reduction in the number of nocturnal voids (NV) compared with baseline. Among 103 patients enrolled, 94 (79 men and 15 women) were included in the analysis. The proportion of patients with a 50% or greater reduction in NV was 68 (72%). The mean number of NV decreased significantly (3.20 to 1.34) and the mean nocturnal urine volume, nocturia index, NPi, and NBCi decreased significantly. The mean duration of sleep until the first NV was prolonged from 118.4 ± 44.1 to 220.3 ± 90.7 min (P<0.001). The overall impression of patients about their quality of sleep improved. Adverse events occurred in 6 patients, including one asymptomatic hyponatremia. Desmopressin is an effective and well-tolerated treatment for mixed nocturia.
为了研究去氨加压素治疗混合性夜尿症的疗效和安全性，招募了年龄≥18 岁的混合性夜尿症（夜间排尿≥2 次，夜间多尿指数[NPi]＞33%，夜间膀胱容量指数[NBCi]＞1）患者。在 3 周的剂量滴定期间确定口服去氨加压素的最佳剂量，并用确定的剂量维持 4 周。通过频率-容量图表和睡眠问卷评估疗效。主要终点是与基线相比，夜间排尿次数（NV）减少 50%或更多的患者比例。在纳入的 103 例患者中，94 例（79 名男性和 15 名女性）纳入分析。68 例（72%）患者 NV 减少 50%或更多。夜间排尿次数明显减少（从 3.20 次减少至 1.34 次），夜间尿量、夜尿指数、NPi 和 NBCi 均明显减少。首次夜间排尿前的平均睡眠时间从 118.4±44.1 分钟延长至 220.3±90.7 分钟（P＜0.001）。患者对睡眠质量的总体印象有所改善。6 例患者发生不良事件，包括 1 例无症状低钠血症。去氨加压素治疗混合性夜尿症有效且耐受性良好。
